Search Submit Your Manuscript

Become A Member

  1. Home
  2. February 2018
  3. 13. Drug Induced Hepatotoxicity and the Risk Factors for Liver Injury During Treatment of Pulmonary Tuberculosis
Article Image
Admin

13. Drug Induced Hepatotoxicity and the Risk Factors for Liver Injury During Treatment of Pulmonary Tuberculosis

Jeando Khan Daidano, Mujahid Chandio, Mukhtiar Abro and Rafique Ahmed Memon

ABSTRACT

Objective: To determine the frequency of drug induced hepatitis due to ATT the presentation of the patient during treatment of pulmonary tuberculosis and the risk factors.

Study Design: Retrospective / Descriptive study.

Place and Duration of Study: This study was conducted at the Department of Medicine at PMCH Nawabshah from August 2015 to August 2017.

Materials and Methods: 100 patients were selected after inclusion criteria on a preformed Performa. Patients selected for this study were from all age groups and gender, diagnosis was made by history, clinical examination of the patient and investigations. All patients were on ATT in pulmonary tuberculosis.

Results: 100 patients participated for this study. 61 were males and 39 were females. Jaundice was present in all the patients, hepatomegaly was noted in 68 patients,  Serum Bilirubin ranged 4.90 to 16 mean10.18 , SGPT ranged 279 to 432 mean 329.31, PT ranged 17-26 mean 21.16. Pyrazinamide was found more hepatotoxic than isoniazid and rifampicin after weekly trial after normalization of SGPT and Bilirubin. Statical analysis was done using software SPSS 15 version.

Conclusion: Due to drug induced hepatitis treatment failure or drug resistant in pulmonary tuberculosis is a big problem. Liver function test during treatment is essential especially in risk factors. Awareness of the patients and their relatives about treatment of pulmonary tuberculosis and drug induced hepatitis is necessary to reduce complications and mortality.

Key Words: Hepatoxicity ATT Pulmonary Tuberculosis

Citation of articles: Drug Induced Hepatotoxicity and the Risk Factors for Liver Injury During Treatment of Pulmonary Tuberculosis. Daidano JK, Chandio M, Abro M, Memon RA. Med Forum 2018;29(2):53-56.